Ultrasound Procedure Detects Uterine Cancer And Disease

November 04, 1998

Researchers at the University of California San Francisco report that a painless, non-invasive ultrasound procedure is able to detect over 95 percent of uterine cancer and disease in postmenopausal women.

The study is published in the Nov. 4 issue of the Journal of American Medical Association.

The test, called an endovaginal ultrasound (EVUS), uses an ultrasound probe that is placed directly into the vagina to obtain a measurement of the uterine lining and detailed images of the uterus.

Researchers found that EVUS was able to identify 96 percent of uterine cancer and 92 percent of uterine disease in postmenopausal women who experience abnormal vaginal bleeding, an indicator of uterine problems.

"This is an excellent test in postmenopausal women who have vaginal bleeding, and it can accurately exclude significant underlying abnormalities, such as uterine cancer," said Rebecca Smith-Bindman, MD, UCSF assistant professor of radiology and lead author of the study. "If a woman's ultrasound results are normal, meaning that she has a thin uterine lining, then there is no need for subsequent invasive testing with a uterine biopsy."

She added that, although many gynecologists are knowledgeable about and may use EVUS in postmenopausal women with vaginal bleeding, few primary care physicians and generalists rely on the test because, until now, there has been a lack of sufficient data proving its efficacy. Smith-Bindman emphasized that physicians need to be thoroughly trained to perform an EVUS examination.

Most postmenopausal women with abnormal vaginal bleeding must undergo a uterine biopsy to determine if they have uterine disease or cancer, the fourth most common malignancy in women in the United States affecting more than 36,000 women and causing 6,300 deaths annually.

However, a standard biopsy, in which part of a woman's uterine tissue is removed to obtain a diagnosis, is uncomfortable, non-diagnostic, or cannot be performed in 2 to 28 percent of attempts, Smith-Bindman said.

Conversely, she added, an ultrasound test is painless, well tolerated, cost-effective, and has a higher accuracy rate for detecting uterine cancer than a biopsy because ultrasound imaging allows visualization of the entire uterine cavity, whereas the latter relies on blind sampling of the uterine tissue. In addition, EVUS eliminates the need for multiple unnecessary biopsies in postmenopausal women who continue to bleed although they have no serious uterine problems.

The ultrasound test is able to accurately measure the lining of a woman's uterus, which is an indicator of uterine cancer or other problems. According to Smith-Bindman, a woman whose uterine lining is greater than 5 mm thick is considered to be at risk of developing uterine cancer or disease, and therefore requires subsequent invasive tests such as a biopsy. However, if her uterine lining is less than 5 mm thick as measured by an ultrasound (0-5 mm is the normal thickness for postmenopausal women), then an invasive test is unnecessary.

During the study, UCSF researchers conducted a search using MEDLINE database of all the studies evaluating EVUS published from January 1966 through November 1996. Studies were included in the analysis if postmenopausal women who experienced vaginal bleeding underwent an EVUS prior to a uterine biopsy. Out of the 85 studies collected, a total of 35 English and non-English studies, including 5892 women, were analyzed.

The mean age of the women in the studies was 61 years and 94 percent experienced vaginal bleeding. Using a 5 mm threshold of uterine thickness to define an abnormal uterine measurement, 96 percent of women with cancer had an abnormal EVUS result, whereas 92 percent of women with uterine disease had an abnormal result. Hormonal replacement therapy, which often increases a woman's uterine lining, did not impact EVUS's ability to detect cancer, Smith-Bindman said.

However, the number of women without uterine problems who had an abnormal EVUS result (false positive test result), did vary by hormone replacement use. For instance, 23 percent of normal women who used hormone replacement therapy had an abnormal EVUS result; whereas 8 percent of normal women who did not use such drugs had an abnormal EVUS result.
-end-
Other researchers on the study include Richard Brand, PhD, UCSF professor of epidemiology and biostatistics; Vickie A. Feldstein, MD, UCSF assistant professor of radiology; Deborah Grady, MD, UCSF associate professor of medicine, epidemiology, and biostatistics; Karla Kerlikowske, MD, UCSF assistant professor of medicine, epidemiology, and biostatistics; Juergen Scheidler, MD, assistant professor of radiology in Heidelberg, Germany; Mark Segal, PhD, UCSF assistant professor of epidemiology and biostatistics; and Leslee Subak, MD, UCSF assistant professor of obstetrics and gynecology.
-end-


University of California - San Francisco

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.